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On page 5722, left column, line 8, the sentence "The percent reduction over placebo in baseline-adjusted seizure frequency/28 days was 9.2% and 20.5% in the BRV 50 and 100 mg/d groups, respectively" should read "The percent reduction over placebo in baseline-adjusted seizure frequency/28 days was 10.2%, 9.2% and 20.5% in the BRV 20, 50 and 100 mg/d groups, respectively".
On page 5722, right column, line 9, the sentence "Responder rate was 21.6% for placebo group, 38.9% for BRV 100 mg/d, and 37.8% for BRV 200 mg/d; the percent reduction of partial onset seizures in 28-day frequency was 22.8% for BRV 100 mg and 23.2% for BRV 200 mg" should read "Responder rate was 21.6% for placebo group, 38.9% for BRV 100 mg/d, and 37.8% for BRV 200 mg/d; the percent reduction of partial onset seizures in 28-day frequency over placebo was 22.8% for BRV 100 mg and 23.2% for BRV 200 mg".
On page 5723, left column, line 22, the sentence "Currently an open-label, multicenter, follow-up study to evaluate the long-term safety and efficacy of BRV is ongoing (BRITE study-NCT01339559)" should read "Currently four openlabel, multicenter, follow-up studies to evaluate the longterm safety and efficacy of BRV are ongoing: N01125 (NCT00175916), N01199 (NCT00150800), N01372 (NCT01728077), and N01379 -BRITE (NCT01339559)".
On page 5724, the first sentence of the Conclusion should read "BRV is a novel AED whose efficacy in partial epilepsies has been studied and established in six randomized controlled trials; [30] [31] [32] [33] [34] [35] furthermore, two recent meta-analyses have confirmed significant effects for BRV in patients with refractory partial seizures. 29, 43 " In the reference list, page 5725, reference 34 (Klein et al), the link should be: http://www.abstracts2view.com/aan/ view.php?nu=AAN15L1_S31.009, which links directly to the abstract text.
